Xencor (XNCR) Tops Q2 EPS by $1.43
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/10/2026
- Wall St futures slip as tech losses mount ahead of key inflation data
- Oil prices rise after Trump says Iran must pay price
- Oracle reports earnings today: Analysts say this metric could 'catalyze higher multiples'
- UBS sees generational semiconductor boom, highlights stock winners
- Has Tesla solved the self-driving puzzle? This analyst thinks so
- Hut 8 Mining Corp. (HUT) PT Raised to $55 at KBW As Management Delivers
- Micron to deliver 'another strong quarter', Goldman says
- UK's Ofcom requires tech firms to create crisis response plans
- Supermicro plans $7 billion financing to fund AI server orders
- S&P 500, Nasdaq fall as tech selling resumes, Trump vows to respond to downed US helicopter
Xencor Reports Second Quarter 2021 Financial Results
August 4, 2021 4:01 PM EDT-- Management to Host Conference Call at 4:30 p.m. ET Today --
MONROVIA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2021 and provided a review of recent business and portfolio highlights.
Xencor is applying its leading protein engineering tools and XmAb technology to overcome historical challenges in creating therapeutic molecules from bispecific antibodies or cytokines. For our most advanced clinical... More
